---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-22-000191"
form_type: "8-K"
ticker: "CHE"
cik: "0000019584"
company_name: "CHEMED CORP"
filed_at: "2022-04-26T23:59:59+00:00"
generated_at: "2026-06-26T04:46:44.496657+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Chemed Q1 2022: EPS up 7.9% on adjusted basis; VITAS revenue down 5.3%, Roto-Rooter up 9.4%

## Summary
- Consolidated revenue $531M (+0.6% YoY); GAAP diluted EPS $4.22 (+5.2%); adjusted diluted EPS $4.79 (+7.9%).
- VITAS net patient revenue $299M (-5.3%), ADC 17,313 (-4.1%), admissions 16,530 (-8.9%).
- Roto-Rooter revenue $231M (+9.4%); net income excl. discrete items $46.4M (+18.0%); adjusted EBITDA margin 28.5% (+160 bps).
- Chemed repurchased 57,500 shares for $27.4M at avg. cost $475.71; remaining auth. ~$175M.
- Management to provide updated 2022 earnings guidance in June 2022 earnings release.

## SEC filing metadata
- accession: 0001562762-22-000191
- form_type: 8-K
- ticker: CHE
- cik: 0000019584
- company_name: CHEMED CORP
- filed_at: 2022-04-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/19584/000156276222000191/0001562762-22-000191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/19584/000156276222000191/che-20220426x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-22-000191
- JSON: https://secwatch.observer/filing/0001562762-22-000191.json
- Plain text: https://secwatch.observer/filing/0001562762-22-000191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.